IL23A and psoriasis: The discovery that the IL-23/IL-17 axis is of major importance for the pathogenesis of psoriasis has been confirmed by the efficacy of new therapeutics (1): in 2009, Ustekinumab (Stelara®), a monoclonal antibody that inhibits the p40 subunit found in both IL-12 and IL-23, was approved for the treatment of psoriasis (75).